Immunotherapies News and Research RSS Feed - Immunotherapies News and Research

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA. [More]
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. [More]
Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

The American Association for Cancer Research and the Cancer Research Institute will recognize Carl H. June, MD, the Richard W. Vague professor in immunotherapy at the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at the University of Pennsylvania in Philadelphia, with the third annual AACR-CRI Lloyd J. Old Award in Cancer Immunology at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22. [More]
People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients. [More]
USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor. [More]
UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. [More]
NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV. [More]
Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

THERAVECTYS, a clinical development biotechnology company that focuses on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant has obtained the status of a pharmaceutical manufacturing establishment, granted by the French National Agency for Medicines and Health Products Safety. [More]
TxCell to present at upcoming US and French investment conferences

TxCell to present at upcoming US and French investment conferences

Damian Marron, CEO, TxCell, will present at the Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25, 2015. In addition, Damian Marron will also participate at the Portzamparc PEA-PME Forum, Paris, April 1, 2015. [More]
Genetic flaws in bowel cancer may trigger immune response at site of tumours

Genetic flaws in bowel cancer may trigger immune response at site of tumours

Scientists have found that genetic changes in bowel tumours are linked to the way the body's immune system responds to the cancer, according to research published today (Monday) in the journal Oncoimmunology. [More]
New triple combination therapy shows promise in controlling advanced melanoma

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
New range of purified, soluble immunoreceptors announced by AMSBIO

New range of purified, soluble immunoreceptors announced by AMSBIO

AMSBIO has announced a new range of purified, soluble immunoreceptors involved in key signalling pathways. Together with new indoleamine 2,3-dioxygenase (IDO) assay kits these products that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies that serve as positive controls for inhibition. [More]
TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell to receive US patent for Ovasave to treat inflammatory bowel disease

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that a key patent is to be granted on March 31 2015 by the United States Patent and Trademark Office. [More]
Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers. [More]
NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach. [More]
Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers. [More]
New approach could dramatically increase survival rate of cancer patients

New approach could dramatically increase survival rate of cancer patients

Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year. [More]
Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Damon Runyon holds fourth annual Accelerating Cancer Cures Research Symposium

Today, the Damon Runyon Cancer Research Foundation held the fourth annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer. [More]
Advertisement
Advertisement